Watch COYA. Know when insiders buy.
One email the day a filing lands. Free.
COYA
Coya Therapeutics, Inc.
4.16
−0.05 −1.19%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
44
WATCH · shorts 44
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $97.6MP/E —DIV YIELD —FCF YIELD —REV TTM $8M +1793.8%NET INCOME −$21.7MNET CASH —52W 3.78 – 7.36SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $244K | +49.0% | — | −$7M | −$6.6M | — | -0.28 | −$7.4M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | $251K | −2.6% | — | −$7.6M | −$7.2M | — | -0.32 | −$6.2M | — | — | Aug 11 |
| Q4 2025 · Dec 31derived | $4M | +202768.8% | — | −$6M | −$5.7M | — | -0.34 | −$1M | — | — | Mar 16 |
| Q3 2025 · Sep 30 | $3.6M | — | — | −$2.4M | −$2.1M | — | -0.13 | −$1.1M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | $164K | −95.2% | — | −$6.4M | −$6.1M | — | -0.36 | −$5.8M | — | — | Aug 11 |
| Q1 2025 · Mar 31 | $258K | +103.3% | — | −$7.7M | −$7.3M | — | -0.44 | −$2.8M | — | — | Aug 11 |
| Q4 2024 · Dec 31derived | $2K | −100.0% | — | −$4.1M | −$2.9M | −330.3% | -0.18 | −$2.4M | — | — | Mar 16 |
| Q3 2024 · Sep 30 | $0 | — | — | −$4.5M | −$4M | — | -0.26 | −$5.5M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | $3.4M | — | — | −$3.2M | −$2.9M | — | -0.19 | −$4.6M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | $127K | — | — | −$5.5M | −$5.1M | — | -0.35 | $2.1M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | $6M | — | — | $1.8M | $1.3M | — | 0.15 | −$2.2M | — | — | Mar 18 |
| Q3 2023 · Sep 30 | $0 | — | — | −$3.6M | −$3.4M | — | -0.34 | −$2.2M | — | — | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $7.9M | — | −$22.6M | −$21.2M | -267.1% | -1.27 | −$10.7M | — | — | — | — |
| FY2024 · to Dec 31 | $3.6M | — | −$17.2M | −$14.9M | -418.7% | -0.98 | −$10.3M | — | — | — | — |
| FY2023 · to Dec 31 | $6M | — | −$7.9M | −$8M | -133.1% | -0.79 | −$11.2M | — | — | — | — |
| FY2022 · to Dec 31 | $0 | — | −$9.8M | −$12.2M | — | -4.73 | −$7.2M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$4.9M | −$4.9M | — | -1.89 | −$3.9M | — | — | — | — |
Every number comes from Coya Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.